Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Public ClinicalTrials.gov record NCT03123588. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
Study identification
- NCT ID
- NCT03123588
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2017
- Primary completion
- Aug 2, 2020
- Completion
- Aug 2, 2020
- Last update posted
- Nov 18, 2021
2017 – 2020
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Ventura County Hematology-Oncology Specialists | Oxnard | California | 93030 | — |
| Compassionate Cancer Care Medical Group | Riverside | California | 92501 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| Bond Clinic, PA | Winter Haven | Florida | 33880 | — |
| Tift Regional | Tifton | Georgia | 31794 | — |
| Edward Cancer Center | Naperville | Illinois | 60540 | — |
| North Shore Cancer Research Association-Skokie | Skokie | Illinois | 60076 | — |
| Southern Illinois University | Springfield | Illinois | 62702 | — |
| Clinical Trials of SWLA LLC | Lake Charles | Louisiana | 70601 | — |
| St. Agnes Hospital | Baltimore | Maryland | 21229 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Summit Medical Group | Morristown | New Jersey | 07960 | — |
| Columbia Weill Cornell Cancer Centers - Herbert Irving Comprehensive Cancer Center (HICCC) | New York | New York | 10032 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Waverly Hem Onc | Cary | North Carolina | 27518 | — |
| Vidant Medical Center | Greenville | North Carolina | 27858 | — |
| Gabrail Cancer Center- Canton Facility | Canton | Ohio | 44718 | — |
| INTEGRIS Southwest Medical Center | Oklahoma City | Oklahoma | 73109 | — |
| INTEGRIS Cancer Institute Proton Campus | Oklahoma City | Oklahoma | 73142 | — |
| Kaiser Permanente Northwest | Portland | Oregon | 97227 | — |
| Geisinger - Knapper Clinic | Danville | Pennsylvania | 17822 | — |
| Prairie Lakes Health Care System Inc. | Watertown | South Dakota | 57201 | — |
| Renovatio Clinical | The Woodlands | Texas | 77401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03123588, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2021 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03123588 live on ClinicalTrials.gov.